Compare BridgeBio Pharma Inc (BBIO) vs ServiceNow Inc (NOW) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

ServiceNow (NOW) trades at $104.85, down 2.66% on the day, amid a generally bullish technical and fundamental backdrop. The stock exhibits strong revenue growth, with 2025 revenue reaching $13.28B and a robust net income margin of 12.59%. Analyst sentiment is overwhelmingly positive, with an 85.51% buy rating and a consensus price target of $137.96, suggesting significant upside potential. Recent news highlights the company's positioning as an 'AI control tower,' with strong performance in May.

The outlook for NOW is favorable, driven by AI adoption and consistent earnings beats, though high valuation multiples (P/E of 66.23) pose a risk if growth slows. Key investment opportunities include expanding profit margins and market share in enterprise software, while risks involve competitive pressures and execution challenges in a high-interest-rate environment.